Long-Term DeFi Data Confirm Durable Efficacy and Consistent Safety of Nirogacestat in Desmoid Tumors
Long-term findings from the phase 3 DeFi trial (NCT03785964) demonstrated sustained efficacy and a consistent safety profile with nirogacestat (Ogsiveo), an oral γ-secretase inhibitor, for the treatment of adult patients with progressing desmoid tumors requiring […]





















